Eli Lilly LLY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Jardiance | $1.11B+44.9% | $768.6M-19.9% | $959M+39.0% | $690M-32.0% | $1.01B-15.4% | |
| Mounjaro | $8.66B+16.9% | $7.41B+13.7% | $6.52B+25.3% | $5.2B+35.3% | $3.84B+8.8% | |
| Neuroscience | $382M-16.8% | $459.2M+45.5% | $315.7M-8.2% | $344M+26.5% | $272M-30.9% | |
| Other cardiometabolic health | $905M-11.0% | $1.02B-4.4% | $1.06B+8.5% | $980.4M+3.7% | $945M-22.5% | |
| Other immunology | $470M-3.9% | $489M+6.1% | $460.9M+13.0% | $408M+25.2% | $326M-3.9% | |
| Other oncology | $966M-3.7% | $1B+7.0% | $937.4M+1.4% | $924.3M+17.1% | $789M-20.9% | |
| Taltz | $733M-30.3% | $1.05B+16.7% | $901.5M+6.4% | $847.6M+11.2% | $762M-19.9% | |
| Trulicity | $919M-11.4% | $1.04B-1.4% | $1.05B-3.7% | $1.09B-0.3% | $1.1B-12.4% | |
| Verzenio | $1.3B-18.9% | $1.6B+9.1% | $1.47B-1.3% | $1.49B+28.5% | $1.16B-25.5% | |
| Zepbound | $4.16B-2.4% | $4.26B+18.7% | $3.59B+6.1% | $3.38B+46.3% | $2.31B+21.2% | |
| Revenue by Geography | ||||||
| China | $693M+46.4% | $473.2M-15.6% | $560.4M+20.3% | $465.9M+3.3% | $451M+5.2% | |
| Europe | $3.65B+17.7% | $3.1B-11.5% | $3.5B+35.9% | $2.57B+7.8% | $2.39B-2.4% | |
| Japan | $571M-12.8% | $654.8M+18.0% | $554.7M+6.5% | $521M+29.6% | $402M-28.1% | |
| Outside U.S. | $7.68B+19.7% | $6.41B+1.8% | $6.3B+32.8% | $4.74B+11.9% | $4.24B-5.8% | |
| Rest of world | $2.77B+26.5% | $2.19B+29.8% | $1.69B+42.8% | $1.18B+18.6% | $997M-6.3% | |
| U.S. | $12.12B-5.9% | $12.88B+14.0% | $11.3B+4.5% | $10.81B+27.4% | $8.49B-6.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Eli Lilly break its business down?
- Eli Lilly (LLY) reports revenue by product across 10 parts — Jardiance, Mounjaro, Neuroscience, Other cardiometabolic health and Other immunology. Each is extracted from the segment footnotes and tracked over time.
- Where does Eli Lilly's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Eli Lilly's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
